Sorrento Therapeutics Inc SRNE
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.05
- Bid/Ask
- — / —
- Shares Outstanding
- 551.28M
- Market Cap
- $441,024.92
- Volume/Avg
- 78,301 / 119,579
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 949
Valuation
|
Metric
|
SRNE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
SRNE
Financial Strength
|
Metric
|
SRNE
|
|---|---|
Quick Ratio | 0.43 |
Current Ratio | 0.50 |
Interest Coverage | −80.16 |
Quick Ratio
SRNE
Profitability
|
Metric
|
SRNE
|
|---|---|
Return on Assets (Normalized) | −71.61% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −231.73% |
Return on Assets
SRNE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|d>t!&HC | LOCK|<>W& | $128B | |||
| Moderna Inc
MRNA
| LOCK|$$g!##y | LOCK|cM | $78B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|vBy?VR@ | LOCK|##cD | $76B | |||
| argenx SE ADR
ARGX
| LOCK|w?nfFM& | LOCK|@>t | $59B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|ZDl!&^ | LOCK|VQv | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|n&h>%PK | LOCK|?l>& | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|GnDkn!JP | LOCK|$>%$ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|D<z?tGz | LOCK|mFq | $24B | |||
| Incyte Corp
INCY
| LOCK|?$>>!g! | LOCK|Dl | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|gp$@bd | LOCK|HK | $15B |
United States